The European Broadcasting Union (EBU) is delighted to announce Novartis as an ‘Official Partner’ for the 69th Eurovision Song Contest when it’s hosted in their hometown in Basel, Switzerland, next May ...
Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...
Novartis CEO Vas Narasimhan assured investors on Tuesday that it takes a careful, systematic approach to M&A after recording an $800 million impairment to its … ...
Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...
Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...
LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...
“We are proud to help redefine CML treatment once again with Scemblix, as we continue to deliver on our 20+ year commitment to innovation and support in CML,” said Victor Bulto, President US, Novartis ...
Novartis on Monday became the latest Big Pharma player to jump into the molecular glue space. The Swiss drugmaker signed an exclusive development and commercialization agreement with Monte Rosa ...
If approved, Kisqali could nearly double the number of patients eligible for CDK4/6 inhibitor adjuvant therapy,” said Patrick Horber M.D., President, International, Novartis. “Together with the recent ...
Novartis Pharmaceuticals Corp. was sued Thursday in federal court by four female pharmaceutical sales managers who say the company discriminated against them based on their age and gender when they ...
As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. In a court decision filed this ...
Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback